Results 111 to 120 of about 40,241 (253)
Bevacizumab Biosimilars: Scientific Justification for Extrapolation of Indications [PDF]
, 2018 Barbara Melosky +5 more
openalex +1 more source
French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025
Journal of the European Academy of Dermatology and Venereology, EarlyView.New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault +51 more
wiley +1 more source
Transfusion, EarlyView.Abstract Background Heparin combined with sodium citrate has been used in leukocytapheresis for pediatric patients. Since 2022, we have performed leukocytapheresis using a highly concentrated sodium citrate solution (HSC, 5.32%) instead of acid citrate dextrose solution A (ACD‐A).
Keiko Fujii +8 more
wiley +1 more source
Review of medicine registration system in Tanzania [PDF]
, 2019 Philosophiae Doctor - PhDRegistration of medicines is an essential function of the national medicine regulatory system of any country. Since the start of the medicine registration system in Tanzania in early 2000s, no systematic review has been carried
KISOMA, SUNDAY
core
Biosimilars: Key regulatory considerations and similarity assessment tools [PDF]
, 2017 Carol F. Kirchhoff +5 more
openalex +1 more source
India's Health Diplomacy: Advancing Pharmaceutical and MedTech Leadership in the Global South
World Medical &Health Policy, Volume 18, Issue 1, March 2026.ABSTRACT Health diplomacy has become a pivotal aspect of India's engagement with the Global South, intertwining foreign policy, public health, and global collaboration to address disparities while pursuing strategic interests. India's pharmaceutical industry, which accounts for nearly 20% of the world's generics, has positioned the nation as the ...
Gaurav Chanderprakash Mittal +4 more
wiley +1 more source
Era of biosimilars in rheumatology: reshaping the healthcare environment
RMD Open, 2019 Compared with the original approved biological drug on which it is based, a biosimilar has highly similar physicochemical characteristics and biological activity, as well as equivalent efficacy and no clinically meaningful differences in safety and ...
J. Smolen +4 more
semanticscholar +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 535-544, February 2026.Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr +18 more
wiley +1 more source